24小时热门版块排行榜

返回列表

【奖励】本帖被评价1次，作者fishhope增加金币 0.8 个

fishhope

铁杆木虫 (正式写手)

应助: 11 (小学生)
金币: 12797.1
帖子: 843
在线: 649.8小时
虫号: 243862

[资源] 《化学前沿》2011年11月（英文版）－Thomson Reuters

IN THIS ISSUE

   The nutlins were first identified by scientists screening a chemical library at Hoffmann-La
   Roche. In this article, we showcase a new synthetic route to (-)-nutlin 3 recently developed
   by Tyler Davis and Jeffrey Johnston of Vanderbilt University, that paves the way into the
   enantioselective arena of nutlin synthesis.

   A wide range of new skeletons emphasize that novel chemical scaffolds with biological activity
   underpin major advances in medicinal chemistry.

   New molecular mechanisms of action are disclosed for a variety of indications.

   This issue includes drugs related to diabetes, cancer and other conditions such as Graves’
   disease and multiple sclerosis.

   In this report, we look at how the downsizing pharmaceutical industry is generating new
   opportunities for the smaller biotechnology and discovery companies. Collaborations between
   large pharma companies and these smaller enterprises, and even university departments and
   their spin-off companies, can help cut the overall risk exposure as well as lower investment
   costs significantly through a focus on developing only those drugs emerging from small
   laboratories that already show a great deal of clinical promise.
   Further to this article, Thomson Reuters has produced a report commemorating the 2011
   International Year of Chemistry, titled “The Changing Role of Chemistry in Drug Discovery”.
   The report explores the themes of this article in greater depth, with the input from many key
   pharmaceutical industry players, and examines how life in drug discovery has changed and
   how it will continue to change and adapt in the future.

回复此楼